SINGAPORE (July 2): In May alone, medical technology company QT Vascular inked deals worth more than $98.4 million to sell the licences and rights to its coronary products to multinational medical companies. A bonanza for shareholders, however, is not quite in sight. In fact, QT Vascular has yet to distribute a dividend since its IPO on the Catalist in 2014. And, shares in the company have been trading comparatively poorly; the stock has a negative return of 96.2% over the last four years. When can shareholders expect a reward for their faith and patience in the company?

On May 24, QT Vascular signed an agreement with Teleflex to sell it the licences for the non-drug-coated Chocolate PTCA Balloon Catheter, and Glider PTCA Balloon Catheter, for $98.4 million. That is more than four times QT Vascular’s market capitalisation. The deal also includes royalties amounting to 5% of net sales from drug-coated coronary balloon catheter Chocolate Heart for the duration of the patents. QT Vascular’s shareholders were unanimous in their support, voting in favour of the deal at an extraordinary general meeting on June 16.

Earlier in the month, the company struck a deal to sell its intellectual property relating to the Chocolate PTCA Balloon Catheter to medical device giant Medtronic for US$28 million ($38 million).

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook